AbbVie Inc. (ABBV) Accounts Payable
The a/p for AbbVie Inc. (ABBV) is $3.59 Billion with a year-over-year change of +21.97%. Accounts Payable (A/P) represents money the company owes to suppliers and vendors for goods and services received but not yet paid for.
ABBV A/P Chart
Current A/P
$3.59B
$3.59 Billion
Year-over-Year Change
+21.97%
vs. $2.94B prior year
Historical Data
16
Years of data available
Annual A/P History
| Year | A/P | YoY Change | % Change |
|---|---|---|---|
| 2025 | $3.59B | +$647.00M | +21.97% |
| 2024 | $2.94B | $-743.00M | -20.15% |
| 2023 | $3.69B | +$754.00M | +25.70% |
| 2022 | $2.93B | +$52.00M | +1.80% |
| 2021 | $2.88B | +$606.00M | +26.63% |
| 2020 | $2.28B | +$824.00M | +56.75% |
| 2019 | $1.45B | $-94.00M | -6.08% |
| 2018 | $1.55B | +$72.00M | +4.88% |
| 2017 | $1.47B | +$67.00M | +4.76% |
| 2016 | $1.41B | $-190.00M | -11.90% |
| 2015 | $1.60B | +$196.00M | +13.99% |
| 2014 | $1.40B | +$468.00M | +50.16% |
| 2013 | $933.00M | +$377.00M | +67.81% |
| 2012 | $556.00M | +$139.00M | +33.33% |
| 2011 | $417.00M | +$60.22M | +16.88% |
| 2010 | $356.78M | — | — |
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael